Roth Capital Has Negative Estimate for TLSI Q2 Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Stock analysts at Roth Capital lowered their Q2 2025 earnings estimates for TriSalus Life Sciences in a research report issued on Wednesday, May 21st. Roth Capital analyst J. Wittes now forecasts that the company will post earnings per share of ($0.19) for the quarter, down from their previous forecast of ($0.11). The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share. Roth Capital also issued estimates for TriSalus Life Sciences’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.72) EPS and FY2026 earnings at ($0.29) EPS.

Other research analysts have also issued research reports about the stock. Roth Mkm reaffirmed a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They set a “buy” rating and a $10.00 target price for the company. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $10.93.

TriSalus Life Sciences Price Performance

Shares of TLSI stock opened at $5.35 on Friday. The firm has a market cap of $172.66 million, a PE ratio of -2.15 and a beta of 0.50. The company has a 50-day moving average of $5.41 and a two-hundred day moving average of $5.03. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $9.85.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The business had revenue of $9.17 million for the quarter, compared to the consensus estimate of $9.04 million. During the same period in the previous year, the business posted ($0.60) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in TriSalus Life Sciences by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock worth $1,023,000 after acquiring an additional 3,710 shares during the last quarter. Northern Trust Corp raised its holdings in TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock worth $161,000 after purchasing an additional 5,936 shares in the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in TriSalus Life Sciences during the first quarter worth approximately $55,000. Renaissance Technologies LLC acquired a new stake in TriSalus Life Sciences during the fourth quarter worth approximately $67,000. Finally, Connective Capital Management LLC acquired a new stake in TriSalus Life Sciences during the fourth quarter worth approximately $140,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

Insider Activity

In other news, insider Richard Marshak sold 6,597 shares of the firm’s stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the transaction, the insider now owns 69,101 shares of the company’s stock, valued at approximately $357,943.18. This trade represents a 8.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders sold 16,125 shares of company stock valued at $83,528. 27.50% of the stock is currently owned by company insiders.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.